For these reasons, while PI3K inhibitors (e.g., GDC-0941) [201] and mTOR inhibitors plus MEK inhibitors (e.g., AZD-8055 plus selumetinib) [202] demonstrate synergistic pro-apoptotic effects with ABT-737 in AML cell lines and patient-derived blasts, accompanied by Bim up-regulation, Mcl-1 down-regulation and Bax activation, dual PI3K/mTOR inhibitors may, in fact, be the superior partner for ABT-737 [192]. Here, MTOR is linked to acute myeloid leukemia.